NASDAQ:TNGX Tango Therapeutics (TNGX) Stock Price, News & Analysis $6.68 -0.09 (-1.33%) Closing price 07/22/2025 04:00 PM EasternExtended Trading$6.63 -0.05 (-0.75%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Tango Therapeutics Stock (NASDAQ:TNGX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tango Therapeutics alerts:Sign Up Key Stats Today's Range$6.36▼$6.8550-Day Range$1.29▼$6.8652-Week Range$1.03▼$12.02Volume1.80 million shsAverage Volume1.61 million shsMarket Capitalization$724.05 millionP/E RatioN/ADividend YieldN/APrice Target$10.50Consensus RatingBuy Company Overview Tango Therapeutics, Inc. (NASDAQ: TNGX) is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts. Founded in 2017, Tango is focused on harnessing the power of synthetic lethality to discover and develop precision oncology therapies. By identifying tumor-specific genetic dependencies, the company aims to create targeted treatments that exploit vulnerabilities unique to cancer cells while sparing healthy tissues. The company’s proprietary discovery engine integrates CRISPR-based genome-wide screening with advanced computational biology to pinpoint novel synthetic lethal interactions. Tango’s pipeline includes multiple wholly owned programs targeting DNA damage repair pathways, as well as immuno-oncology and metabolic vulnerabilities. Lead assets are advancing through preclinical validation and into early-stage clinical trials, with several IND submissions anticipated in the coming years. Tango has forged strategic collaborations with leading pharmaceutical partners to co-develop select programs and expand its therapeutic reach. These alliances leverage Tango’s expertise in target identification alongside partners’ clinical development and commercialization capabilities. The company is led by CEO Debora Barton, Ph.D., whose leadership team brings deep experience in oncology drug discovery, translational research and global biopharmaceutical operations. Operating primarily in the United States, Tango maintains research and development facilities in Kendall Square and collaborates with academic institutions and contract research organizations worldwide. Committed to advancing next-generation cancer medicines, the company’s mission is to deliver differentiated therapies that offer new treatment options for patients with high unmet medical need across diverse tumor types.AI Generated. May Contain Errors. Read More Tango Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks27th Percentile Overall ScoreTNGX MarketRank™: Tango Therapeutics scored higher than 27% of companies evaluated by MarketBeat, and ranked 739th out of 917 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingTango Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageTango Therapeutics has received no research coverage in the past 90 days.Read more about Tango Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Tango Therapeutics are expected to decrease in the coming year, from ($1.19) to ($1.38) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Tango Therapeutics is -5.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Tango Therapeutics is -5.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTango Therapeutics has a P/B Ratio of 3.59. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Tango Therapeutics' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted35.96% of the float of Tango Therapeutics has been sold short.Short Interest Ratio / Days to CoverTango Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Tango Therapeutics has recently increased by 35.23%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTango Therapeutics does not currently pay a dividend.Dividend GrowthTango Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted35.96% of the float of Tango Therapeutics has been sold short.Short Interest Ratio / Days to CoverTango Therapeutics has a short interest ratio ("days to cover") of 7.8.Change versus previous monthShort interest in Tango Therapeutics has recently increased by 35.23%, indicating that investor sentiment is decreasing significantly. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Tango Therapeutics this week, compared to 3 articles on an average week.Search Interest15 people have searched for TNGX on MarketBeat in the last 30 days. This is an increase of 275% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Tango Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tango Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.50% of the stock of Tango Therapeutics is held by insiders.Percentage Held by Institutions78.99% of the stock of Tango Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Tango Therapeutics' insider trading history. Receive TNGX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tango Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TNGX Stock News HeadlinesTNGX - Tango Therapeutics Inc News - MorningstarJuly 16, 2025 | morningstar.comMTango Therapeutics doses first patient in cancer drug combo trialJune 29, 2025 | uk.investing.comTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans a chance at true financial independence in the months ahead.” We recently sat down with Rickards to capture all the key details on tape. July 23 at 2:00 AM | Paradigm Press (Ad)Tango Therapeutics Shares Climb After First Patient Dosed in Pancreatic, Lung Cancer TrialJune 27, 2025 | marketwatch.comTango Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of TNG462 plus Revolution Medicines' Daraxonrasib or Zoldonrasib in Patients with RAS-Mutant MTAP-deleted Pancreatic or Lung CancerJune 27, 2025 | globenewswire.comTango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last? - NasdaqJune 25, 2025 | nasdaq.comTango Therapeutics’ SWOT analysis: stock poised for growth amid clinical trialsJune 16, 2025 | investing.comTango Therapeutics: PRMT5 Data Readout Due In 2025 Is CriticalJune 6, 2025 | seekingalpha.comSee More Headlines TNGX Stock Analysis - Frequently Asked Questions How have TNGX shares performed this year? Tango Therapeutics' stock was trading at $3.09 on January 1st, 2025. Since then, TNGX stock has increased by 116.2% and is now trading at $6.68. How were Tango Therapeutics' earnings last quarter? Tango Therapeutics, Inc. (NASDAQ:TNGX) issued its quarterly earnings data on Monday, May, 12th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by $0.02. The company had revenue of $5.39 million for the quarter, compared to analyst estimates of $6.73 million. Tango Therapeutics had a negative trailing twelve-month return on equity of 62.75% and a negative net margin of 322.67%. How do I buy shares of Tango Therapeutics? Shares of TNGX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Tango Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Tango Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Palo Alto Networks (PANW), Adobe (ADBE) and ServiceNow (NOW). Company Calendar Last Earnings5/12/2025Today7/23/2025Next Earnings (Estimated)8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:TNGX CIK1819133 Webwww.tangotx.com Phone857-320-4900FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Price Target for Tango Therapeutics$10.50 High Price Target$13.00 Low Price Target$8.00 Potential Upside/Downside+57.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$130.30 million Net Margins-322.67% Pretax Margin-322.17% Return on Equity-62.75% Return on Assets-39.94% Debt Debt-to-Equity RatioN/A Current Ratio6.26 Quick Ratio6.26 Sales & Book Value Annual Sales$42.07 million Price / Sales17.21 Cash FlowN/A Price / Cash FlowN/A Book Value$1.86 per share Price / Book3.59Miscellaneous Outstanding Shares108,390,000Free Float100,264,000Market Cap$724.05 million OptionableOptionable Beta1.63 A Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free Report This page (NASDAQ:TNGX) was last updated on 7/23/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?Bitcoin is breaking out — and one state just created a Strategic Crypto Reserve. James Altucher says this m...Paradigm Press | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tango Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tango Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.